🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

CVS raises 2020 earnings forecast as fewer insurance claims boost second-quarter profit

Published 08/05/2020, 06:48 AM
Updated 08/05/2020, 08:15 AM
© Reuters. The CVS logo is seen at one of their stores in Manhattan, New York, U.S.
ELV
-
CVS
-
UNH
-

(Reuters) - CVS Health Corp (N:CVS) raised its full-year profit forecast and beat Wall Street expectations for quarterly profit on Wednesday, as a drop in non-urgent medical procedures due to the COVID-19 pandemic led to fewer claims at its health insurance business.

Hospitals also rescheduled elective surgeries to reduce the burden on the healthcare system as coronavirus cases surged, benefiting health insurers including CVS Health and Humana Inc (N:HUM), which also beat quarterly profit estimates on Wednesday, as claims fell.

Shares of CVS, which also operates drugstores, rose nearly 4% in premarket trade.

The medical benefit ratio - the percentage of premiums paid out for medical services - at CVS' health insurance unit fell to 70.3% from 84% a year earlier. Sales at the unit rose 6.1% to $18.47 billion.

CVS like other health insurers including industry bellwether UnitedHealth (N:UNH) has warned that costs may go up in the remainder of the year as Americans catch up on their postponed surgeries.

Best known for its chain of pharmacies, CVS acquired a health insurance business through its 2018 deal for Aetna (NYSE:AET), and also operates a pharmacy benefit management unit.

"Our earnings in this environment demonstrate the strength of our strategy and the power of our diversified business model," said CVS Chief Executive Officer Larry Merlo in a statement.

The company raised its full-year profit forecast to between $7.14 per share and $7.27 per share from $7.04 per share to $7.17 per share

Net income attributable to the company rose nearly 54% to $2.98 billion in the second-quarter ended June 30, compared with a year earlier

© Reuters. The CVS logo is seen at one of their stores in Manhattan, New York, U.S.

Excluding items, the company earned $2.64 per share, beating analysts' average estimate of $1.93, according to IBES data from Refinitiv.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.